Document is current
Any future updates will be listed below
-
Authors
Monteil, Vanessa https://orcid.org/0000-0002-2652-5695
Dyczynski, Matheus https://orcid.org/0000-0002-7650-3574
Lauschke, Volker M https://orcid.org/0000-0002-1140-6204
Kwon, Hyesoo
Wirnsberger, Gerald
Youhanna, Sonia https://orcid.org/0000-0002-9376-8478
Zhang, Haibo https://orcid.org/0000-0002-1714-3038
Slutsky, Arthur S https://orcid.org/0000-0002-6063-3876
Hurtado del Pozo, Carmen
Horn, Moritz https://orcid.org/0000-0002-5324-7256
Montserrat, Nuria https://orcid.org/0000-0002-1603-1755
Penninger, Josef M https://orcid.org/0000-0002-8194-3777
Mirazimi, Ali https://orcid.org/0000-0003-2371-6055
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (440347)
Canadian Institutes of Health Research (FDN143285)
Canadian Institutes of Health Research (OV3‐170344)
Vienna Science and Technology Fund
H2020 European Research Council
Innovative Medicines Initiative (101005026)
Centres de Recerca de Catalunya
H2020 Marie Skłodowska-Curie Actions
Fundación Científica Asociación Española Contra el Cáncer
Centres de Recerca de Catalunya (2017 SGR 1306)
Fundación Científica Asociación Española Contra el Cáncer (LABAE16006)
Vetenskapsrådet (2018‐05766)
Boehringer Ingelheim
- License Information
-
More Information
Article History
Received: 9 September 2020
Revised: 6 November 2020
Accepted: 10 November 2020
First Online: 14 December 2020
Conflict of interest
: JMP declares a conflict of interest as a founder and shareholder of Apeiron Biologics. GW is an employee of Apeiron Biologics. AS is a consultant to Apeiron Biologics. VML is co‐founder, CEO, and shareholder of HepaPredict AB and discloses consultancy work for Enginzyme AB. MH is co‐founder, CEO, and shareholder of Acus Laboratories GmbH and CSO of JLP Health GmbH. MD is employee of Acus Laboratories GmbH and JLP Health GmbH. All other authors declare no competing interests.
